drugset / Trial / NCT01760122
Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
Phase 3
Completed
820 enrolled
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-07
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 180 ug | Subcutaneous |